N4 Pharma Income Statement

Financials in millions GBP. Fiscal year is January - December.

Millions GBP. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2016
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2016
Operating Revenue	0.01	0.01	0	-	-	-	Upgrade
Revenue	0.01	0.01	0	-	-	-	Upgrade
Revenue Growth (YoY)	20.60%	272.86%	-	-	-	-	Upgrade
Gross Profit	0.01	0.01	0	-	-	-	Upgrade
Selling, General & Admin	0.86	0.84	0.72	0.62	0.66	0.66	Upgrade
Research & Development	0.34	0.39	0.62	0.58	1.18	0.9	Upgrade
Operating Expenses	1.21	1.23	1.34	1.19	1.84	1.56	Upgrade
Operating Income	-1.2	-1.22	-1.34	-1.19	-1.84	-1.56	Upgrade
Interest & Investment Income	0	-	-	0	0	-	Upgrade
Currency Exchange Gain (Loss)	-	-	-	-	-	-0	Upgrade
Other Non Operating Income (Expenses)	-	-	-0.09	-	-	-0	Upgrade
EBT Excluding Unusual Items	-1.2	-1.22	-1.42	-1.19	-1.84	-1.57	Upgrade
Pretax Income	-1.2	-1.22	-1.42	-1.19	-1.84	-1.57	Upgrade
Income Tax Expense	-0.07	-0.1	-0.15	-0.16	-0.3	-0.26	Upgrade
Earnings From Continuing Operations	-1.13	-1.12	-1.28	-1.03	-1.54	-1.3	Upgrade
Minority Interest in Earnings	0.03	0.06	0.01	-	-	-	Upgrade
Net Income	-1.1	-1.06	-1.27	-1.03	-1.54	-1.3	Upgrade
Net Income to Common	-1.1	-1.06	-1.27	-1.03	-1.54	-1.3	Upgrade
Shares Outstanding (Basic)	486	340	243	186	181	136	Upgrade
Shares Outstanding (Diluted)	486	341	243	186	181	136	Upgrade
Shares Change (YoY)	80.86%	40.34%	30.29%	2.95%	32.85%	36.08%	Upgrade
EPS (Basic)	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01	Upgrade
EPS (Diluted)	-0.00	-0.00	-0.01	-0.01	-0.01	-0.01	Upgrade
Gross Margin	100.00%	100.00%	100.00%	-	-	-	Upgrade
Operating Margin	-17000.69%	-16768.76%	-68377.83%	-	-	-	Upgrade
Profit Margin	-15600.13%	-14537.52%	-64993.91%	-	-	-	Upgrade
EBIT	-1.2	-1.22	-1.34	-1.19	-1.84	-1.56	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.